TTD Research Update — September 18, 2026
Updated Thesis
The Trade Desk operates a self-service, cloud-based demand-side platform that lets advertising agencies and their advertiser clients plan, buy and optimize data-driven digital campaigns across display, video, audio, native, social and connected TV, with 3,843 employees and a founder-led management team. Business quality is genuinely high on the unit economics: TTM gross margin of 83.0%, TTM operating margin of 19.6%, TTM net margin of 13.6%, ROE of 16.1% and free cash flow of $1.84 per share against $6.36 of revenue per share, which is why the shares change hands at only 7.76 times free cash flow and 7.52 times EV/EBITDA. The problem is that the growth engine has stalled: revenue rose just 3.0% year over year in the most recent quarter while earnings fell 28.6% year over year in that same quarter, and Amazon's ad revenue grew 26% in the comparable period, so the market is pricing TTD as a decelerating, competitively pressured asset rather than the compounder it was.
The investment grade as of this refresh is C — average business quality. B-tier business, C-tier valuation: 1.8% downside to $14.00 fair value.
Grade Change
In this research cycle, the investment grade for The Trade Desk, Inc. moved from B- to C. B-tier business, C-tier valuation: 1.8% downside to $14.00 fair value.
Key Metrics at a Glance
- Revenue growth: +3.0% year over year
- Net margin: 13.6%
- Fair value upside: -1.8% to our estimate of $14
Current price: $14.26
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. The Trade Desk, Inc. remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full TTD research →](/stocks/TTD)